This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone Sep 2026 quarter: revenue up 5.1% year on year; EBITDA margin narrows; results approved
KRONOX · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 1.7 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone quarter ended Sep 30, 2026: revenue rose 5.1% year on year to Rs 2,683.42 lakh and profit after tax fell 3.5% to Rs 644.03 lakh. EBITDA margin narrowed to 31.4%. Standalone half-year: revenue Rs 5,522.06 lakh, net profit Rs 1,374.33 lakh, operating cash flow Rs 1,604.13 lakh. Indo Borax took 64.26% control on Sep 29; auditor flagged the board and management change but raised no objection. Prior figures were regrouped or reclassified.
Lower profit and a narrower margin may weigh on the stock, while strong cash flow and Indo Borax's control may support it.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹55.22 Cr | ₹25.53 Cr | +116.3% |
| Operating profit | ₹16.38 Cr | ₹8.14 Cr | +101.3% |
| Profit after tax | ₹13.74 Cr | ₹6.68 Cr | +105.9% |
| EBITDA margin | 31.6% | 33.9% | −2.3 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.